Karen S. Lynch's most recent trade in Thermo Fisher Scientific Inc. was a trade of 76 Phantom Stock Units done . Disclosure was reported to the exchange on June 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Thermo Fisher | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2025 | 76 | 104 | - | - | Phantom Stock Units | |
| Thermo Fisher | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 565 | 660 (0%) | 0% | 0 | Common Stock | |
| Thermo Fisher | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2025 | 27 | 27 | - | - | Phantom Stock Units | |
| Thermo Fisher | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 95 | 95 (0%) | 0% | 0 | Common Stock | |
| CVS Health | Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2024 | 188,087 | 188,087 | - | - | Stock Option | |
| CVS Health | Karen S. Lynch | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 79.56 per share. | 01 Apr 2024 | 61,953 | 74,687 (0%) | 0% | 79.6 | 4,928,981 | Common Stock |
| CVS Health | Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 79.56 per share. | 01 Apr 2024 | 45,248 | 45,248 | - | 79.6 | 3,599,931 | Common Stock (Restricted) |
| CVS Health | Karen S. Lynch | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 69.75 per share. | 03 May 2023 | 14,000 | 431,392 (0%) | 0% | 69.8 | 976,567 | Common Stock (By Trust) |
| CVS Health | Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2023 | 244,952 | 244,952 | - | - | Stock Option | |
| CVS Health | Karen S. Lynch | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.31 per share. | 01 Apr 2023 | 93,677 | 112,933 (0%) | 0% | 74.3 | 6,961,138 | Common Stock |
| CVS Health | Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 206,610 | 206,610 (0%) | 0% | 0 | Common Stock | |
| CVS Health | Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 171,517 | 171,517 | - | - | Stock Option | |
| CVS Health | Karen S. Lynch | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 101.09 per share. | 01 Apr 2022 | 116,940 | 210,090 (0%) | 0% | 101.1 | 11,821,465 | Common Stock |
| CVS Health | Karen S. Lynch | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2022 | 257,916 | 327,030 (0%) | 0% | 0 | Common Stock | |
| U.S. Bancorp | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2021 | 13 | 7,796 | - | - | Deferred Compensation Plan Participation | |
| CVS Health | Karen S. Lynch | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.52 per share. | 28 Nov 2021 | 14,121 | 69,114 (0%) | 0% | 91.5 | 1,292,354 | Common Stock |
| U.S. Bancorp | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2021 | 1,211 | 7,669 | - | - | Deferred Compensation Plan Participation | |
| U.S. Bancorp | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Apr 2021 | 2,849 | 2,849 | - | - | Restricted Stock Units | |
| CVS Health | Karen S. Lynch | EVP and President, Aetna | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 224,604 | 224,604 | - | - | Stock Option | |
| CVS Health | Karen S. Lynch | EVP and President, Aetna | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2021 | 95,302 | 95,302 (0%) | 0% | 0 | Common Stock | |
| CVS Health | Karen S. Lynch | EVP and President, Aetna | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.30 per share. | 01 Feb 2021 | 43,211 | 52,091 (0%) | 0% | 74.3 | 3,210,577 | Common Stock |
| U.S. Bancorp | Karen S. Lynch | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2020 | 33 | 6,365 | - | - | Deferred Compensation Plan Participation | |
| CVS Health | Karen S. Lynch | EVP and President, Aetna | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.63 per share. | 02 Dec 2020 | 12,779 | 94,370 (0%) | 0% | 69.6 | 889,802 | Common Stock |